How is overall survival assessed in randomised clinical trials in cancer and are subsequent treatment lines considered? A systematic review
Abstract Background Overall survival is the “gold standard” endpoint in cancer clinical trials. It plays a key role in determining the clinical- and cost-effectiveness of a new intervention and whether it is recommended for use in standard of care. The assessment of overall survival usually requires...
Main Authors: | Kara-Louise Royle, David Meads, Jennifer K. Visser-Rogers, Ian R. White, David A. Cairns |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-11-01
|
Series: | Trials |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13063-023-07730-1 |
Similar Items
-
Effect of subsequent bladder cancer on survival in upper tract urothelial carcinoma patients post-radical nephroureterectomy: a systematic review and meta-analysis
by: Haopu Hu, et al.
Published: (2023-12-01) -
Heterogeneity in pragmatic randomised trials: sources and management
by: Bruno Giraudeau, et al.
Published: (2022-10-01) -
The reliability and integrity of overall survival data based on follow-up records only and potential solutions to the challenges
by: Huiyao Huang, et al.
Published: (2023-02-01) -
A systematic review of randomised controlled trials with adaptive and traditional group sequential designs – applications in cardiovascular clinical trials
by: Jufen Zhang, et al.
Published: (2023-09-01) -
Subsequent management and outcomes after first-line PARP inhibitors progression in ovarian cancer patients
by: Hua Yuan, et al.
Published: (2024-04-01)